SCHEMBL4770733

SCHEMBL4770733

Cc1ccccc1CC(N)C(=O)N1CCN(C(=O)c2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.54
DPP4 P27487 3/20 0.51
ALDH1A1 P00352 2/20 0.51
GAA P10253 1/20 0.51
FAP Q12884 1/20 0.51
DPP8 Q6V1X1 1/20 0.51
DPP9 Q86TI2 1/20 0.51
BLM P54132 1/20 0.49
FABP6 P51161 1/20 0.48
CYP3A4 P08684 1/20 0.46
POLB P06746 2/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
OPRK1 P41145 3/20 0.46
DPP7 Q9UHL4 1/20 0.46
HTT P42858 1/20 0.45
MAOB P27338 1/20 0.45
GRIN2B Q13224 1/20 0.45
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775342 0.85 AKT1 (0.57) DPP4ALDH1A1BLMCYP3A4KDM4E
SCHEMBL4773494 0.85 DPP4 (0.55) DPP4ALDH1A1FAPDPP8DPP9
SCHEMBL4776632 0.82 NPSR1 (0.55) L3MBTL1DPP4ALDH1A1FAPDPP8
SCHEMBL4779980 0.81 ALDH1A1 (0.62) DPP4ALDH1A1FAPDPP8DPP9
SCHEMBL4772716 0.80 AKT1 (0.57) DPP4CYP3A4
SCHEMBL4777024 0.79 CHRM2 (0.56) L3MBTL1ALDH1A1POLBLMNAOPRK1
SCHEMBL4795470 0.79 HDAC8 (0.65) DPP4FAPDPP8DPP9DPP7
SCHEMBL4795016 0.78 HDAC8 (0.67)
SCHEMBL4775325 0.77 CYP2C19 (0.51) DPP4ALDH1A1DPP8DPP9BLM
SCHEMBL4776526 0.77 ALDH1A1 (0.46) L3MBTL1DPP4ALDH1A1DPP8BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof HNMT, HDAC5, HDAC4 L3MBTL1 2113/4885DPP4 616/4885ALDH1A1 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.